The data shown on this page comes from Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries.
A critical factor when examining service provider selection is the existence of preferred provider agreements. Keeping this in mind, ISR asks respondents to share their selection criteria in a way that demonstrates these agreements’ impacts on the decision-making process.
For companies considering life cycle extension strategies for their oral-dose products, there are clear preferences as to which strategies they would pursue.
ISR research indicates that proactive communication between sponsors and CMOs in these three areas will help to improve outsourcing relationships. Data comes from ISR’s Development and Commercial Outsourcing Models market research report.
As part of our yearly service provider quality benchmarking, Industry Standard Research asks late-phase decision makers to select their top five most important attributes when outsourcing with no preferred providers.
Outsourcing motivations are important considerations to identifying the best outsourcing approach and should influence the type of relationships your organization develops with CMOs. Data comes from ISR’s CMO Quality Benchmarking suite of market research reports and ISR’s Development and Commercial Outsourcing Models market research report.
ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.
Almost half of survey respondents report their companies use formal preferred provider agreements (PPAs) for their Phase 2/3 outsourcing.
ISR recently surveyed decision makers across all phases of clinical development to gain insight on sponsor/CRO dynamics. More than half of respondents agreed (to some level)that their organization would change its mix of CROs.
ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.
A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.
A look at which departments at sponsor organizations are involved in the decision-making process and how much decision-making responsibility each department has for outsourcing various late-phase study activities.
Understanding which attributes industry peers feel are important can help in the process of CRO selection.
When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.
ISR asked study sponsors, CROs, and clinical research sites what’s the most important attribute they would use to select an eCOA (electronic clinical outcomes assessment)/ePRO (electronic patient reported outcomes) provider for development-stage products.
2017 was another strong year for CRO growth, with all major/public service providers experiencing year-over-year revenue gains. The largest component of CRO market revenue by geography, development, and service line is highlighted here.
Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.
The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.
The 10th Edition of ISR’s CRO Quality Benchmarking Suite comes out this year. Here we take a look at how the CRO landscape has changed throughout the past decade.
Integration with eClinical software applications will drive IRT (interactive response technology) enhancements, but it is important to many study sponsors that IRT be delivered though companies that specialize in this technology.
What is the effect of a near-record volume of drug approvals? Just think about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities.
Pfizer’s top scientist, Mikael Dolsten, M.D., Ph.D., talks about being hyper focused during company’s R&D turnaround amongst CEO turnover, company integrations and M&A.
Robert Hariri, M.D., Ph.D., discusses how he became friends with life coach Tony Robbins, and why Robbins decided to invest in his company.
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.
Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.
Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.